Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 8

Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment

Authors Gérard A, Liard F, Crochard A, Goni S, Millet B

Published Date December 2012 Volume 2012:8 Pages 605—614

DOI http://dx.doi.org/10.2147/NDT.S34132

Received 23 May 2012, Accepted 2 August 2012, Published 13 December 2012

Alain Gérard,1 François Liard,2 Anne Crochard,3 Sylvia Goni,3 Bruno Millet4

1Rue des Marronniers’ Psychiatry Clinic, Paris; 2General Practice, Saint Epain, 3Medical Affairs Department, Laboratoire Lundbeck SAS, Issy-Les-Moulineaux, 4Psychiatry Department, Guillaume Regner University Hospital, University of Rennes 1, Rennes, France

Background: The primary objective of this prospective observational study was to evaluate changes in self-reported disability in patients with anxiety or mood disorders 3 months after initiating antidepressant treatment.
Methods: This study included 8396 patients consulting 2433 general practitioners in France for a major mood episode, generalized anxiety disorder, social anxiety disorder, panic disorder, or obsessive-compulsive disorder. Treatment was initiated with the antidepressant that the physician considered appropriate. Patients were evaluated with the Sheehan Disability Scale (SDS), Hospital Anxiety and Depression Scale, and Clinical Global Impression-Severity (CGI-S) at baseline and after 6 and 12 weeks.
Results: At 12 weeks, 6617 patients (78.8%) were evaluable. At inclusion, the mean SDS subscores were 6.5 ± 2.2 on the work/school activities dimension, 6.8 ± 1.9 on the social activities dimension, and 6.5 ± 2.0 on the family life dimension. At the 12-week follow-up visit, the mean change in score on these three dimensions was -3.9 ± 2.6, -4.2 ± 2.5, and -4.0 ± 2.5, respectively. At the 12-week follow-up visit, 90.0% of patients were responders (defined as patients whose SDS dimension scores decreased by at least one point) on the work/school SDS subscores; 92.8% were responders on the social life SDS subscores, and 91.1% were responders on family life/home responsibilities SDS subscores. Functional remission (defined as an SDS subscore of 0 at study end) rates were 18.0% for the work/school dimension, 16.8% for the social activities dimension, and 19.5% for the family life dimension. Using a cutoff of ≤2, remission rates were 56.8%, 55.0%, and 58.0%, respectively. Improvements in self-rated disability were correlated with improvements in symptoms measured with clinician-rated
CGI-S.
Conclusion: Patients consulting for anxiety or mood disorders report significant disability, which can be effectively reduced by antidepressant treatment.

Keywords: depression, anxiety disorder, antidepressant, disability

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Differential attentional bias in generalized anxiety disorder and panic disorder

Chen J, Wang Z, Wu Y, Cai Y, Shen Y, Wang L, Shi S

Neuropsychiatric Disease and Treatment 2013, 9:73-80

Published Date: 8 January 2013

The association of drooling and health-related quality of life in children with cerebral palsy

Chang SC, Lin CK, Tung LC, Chang NY

Neuropsychiatric Disease and Treatment 2012, 8:599-604

Published Date: 11 December 2012

Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies

Kristinsson J, Snaedal J, Tórsdóttir G, Jóhannesson T

Neuropsychiatric Disease and Treatment 2012, 8:515-521

Published Date: 2 November 2012

Can headache impair intellectual abilities in children? An observational study

Esposito M, Pascotto A, Gallai B, Parisi L, Roccella M, Marotta R, Lavano SM, Gritti A, Mazzotta G, Carotenuto M

Neuropsychiatric Disease and Treatment 2012, 8:509-513

Published Date: 1 November 2012

Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression

Myczkowski ML, Dias AM, Luvisotto T, Arnaut D, Bellini BB, Mansur CG, Rennó J, Tortella G, Ribeiro PL, Marcolin MA

Neuropsychiatric Disease and Treatment 2012, 8:491-500

Published Date: 25 October 2012

Effectiveness of sensory processing strategies on activity level in inclusive preschool classrooms

Lin CL, Min YF, Chou LW, Lin CK

Neuropsychiatric Disease and Treatment 2012, 8:475-481

Published Date: 23 October 2012

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?

Mezei Z, Bereczki D, Racz L, Csiba L, Csepany T

Neuropsychiatric Disease and Treatment 2012, 8:465-473

Published Date: 23 October 2012